Merck Prices $ 6.5 Billion Debt Offering


May 15, 2013 5:29 pm ET

Merck & Co., Inc. priced today a $6.5 billion public offering of senior
unsecured notes. The notes include:

$1,000 million of 0.70% notes due May 2016
$500 million of floating
rate notes due May 2016
$1,000 million of 1.30% notes due May 2018
million of floating rate notes due May 2018
$1,750 million of 2.80%
notes due May 2023
$1,250 million of 4.15% notes due May 2043

Proceeds from the notes will be used to repurchase our common stock and
any remaining proceeds will be used for general corporate purposes,
including without limitation the repayment of outstanding commercial
paper borrowings and upcoming debt maturities. The offering is expected
to close on May 20, 2013, subject to customary closing conditions. BNP
Paribas Securities Corp., Deutsche Bank Securities Inc., J. P. Morgan
Securities LLC and Morgan Stanley & Co. LLC are acting as active joint
book-running managers for the offering.

This release does not constitute an offer to sell or a solicitation of
an offer to buy the securities described herein, nor shall there be any
sale of these securities in any state or jurisdiction in which such an
offer, solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such jurisdiction. The
offering may be made only by means of a prospectus supplement and
accompanying base prospectus. When available, copies of the prospectus
supplement and accompanying base prospectus related to the offering may
be obtained from BNP Paribas Securities Corp. toll-free at
1-800-854-5674, Deutsche Bank Securities Inc. toll-free at
1-800-503-4611, J.P. Morgan Securities LLC collect at 1-212-834-4533 or
Morgan Stanley & Co. LLC toll-free at 1-866-718-1649.

About Merck

Today’s Merck is a global healthcare leader working to help the world be
well. Merck is known as MSD outside the United States and Canada.
Through our prescription medicines, vaccines, biologic therapies, and
consumer care and animal health products, we work with customers and
operate in more than 140 countries to deliver innovative health
solutions. We also demonstrate our commitment to increasing access to
healthcare through far-reaching policies, programs and partnerships.

Forward-Looking Statement

This news release includes “forward-looking statements” within the
meaning of the safe harbor provisions of the United States Private
Securities Litigation Reform Act of 1995. These statements are based
upon the current beliefs and expectations of Merck’s management and are
subject to significant risks and uncertainties. If underlying
assumptions prove inaccurate or risks or uncertainties materialize,
actual results may differ materially from those set forth in the
forward-looking statements.

Risks and uncertainties include but are not limited to, general industry
conditions and competition; general economic factors, including interest
rate and currency exchange rate fluctuations; the impact of
pharmaceutical industry regulation and health care legislation in the
United States and internationally; global trends toward health care cost
containment; technological advances, new products and patents attained
by competitors; challenges inherent in new product development,
including obtaining regulatory approval; Merck’s ability to accurately
predict future market conditions; manufacturing difficulties or delays;
financial instability of international economies and sovereign risk;
dependence on the effectiveness of Merck’s patents and other protections
for innovative products; and the exposure to litigation, including
patent litigation, and/or regulatory actions.

Merck undertakes no obligation to publicly update any forward-looking
statement, whether as a result of new information, future events or
otherwise. Additional factors that could cause results to differ
materially from those described in the forward-looking statements can be
found in Merck’s 2012 Annual Report on Form 10-K and the company’s other
filings with the Securities and Exchange Commission (SEC) available at
the SEC’s Internet site (

Merck & Co., Inc.
Media Contact:
Steven Cragle, 908-423-3461
Investor Contact:
Carol Ferguson, 908-423-5185

Unsubscribe from email alerts